Abstract
Introduction: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells (HPSC) in the bone marrow. The Iraqi cancer registry announced that Chronic Myeloproliferative disorders in male has 0.62% incidence rate and 0.36, in female Chronic Myeloproliferative disorders 45case 0.31% and incidence rate 0.24. The JAK2-V617F mutation is approximately 70% presented in the myeloproliferative neoplasm cases. This is a somatic mutation that concern changing of the amino acid valine to phenylalanine at codon region 617 (that’s why it’s called JAK2-V617F) presented in the pseudo kinase domain. JAK2-V617F mutation is 50% to 70% in Essential Thrombocythemia (ET), 40% to 50% in Primary Myelofibrosis (PMF), and 95% in Polycythemia Vera (PV). IL-8 elevated level in MPNs has a major part in the presence of symptoms.

Materials and Methods: Total of (60) patients screened by cohort prospective study of having MPN who are patients presented to the National Center of Hematology / AlMustansiriyah university, Depending on JAK2-V617F mutation we classified the patients into 3 groups: JAK2-V617F positive (N: 40), JAK2-V617F negative (N: 20) and control group. Blood sample (5) ml was obtained from each individual in each group, by venipuncture using disposable syringes for IL-8 serum estimation.

Results: A clear indication of significant differences is seen between IL-8 serum level in JAK2-V617F negative group and control group (P < 0.05). Also, a significant difference occurred among IL-8 serum level in JAK2-V617F positive samples and IL-8 serum level of JAK2-V617F negative samples.

Conclusion: IL-8 serum level in all MPN patients is high as a part of chronic inflammation, But, IL-8 serum level of JAK2-V617F negative group is higher than the JAK2-V617F positive group due to many reasons like the source of IL8 is not related to the JAK2-V617F mutation.

Key words: Interleukin 8 serum level, MPN, JAK2-V617F negative, JAK2-V617F positive.